Amphista Therapeutics
Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026.
Overview
Amphista Therapeutics is a Cambridge, UK targeted protein degradation company whose Targeted Glue degraders deploy novel E3 ligases beyond cereblon, chosen for each target. Its lead programme, AMX-883, is an orally bioavailable, selective DCAF16-mediated BRD9 degrader for acute myeloid leukaemia that releases the differentiation block in a broad AML population, shows in vivo efficacy alone and synergy with venetoclax, and received FDA clearance of its IND application in June 2026 as the first BRD9-targeted therapy for AML. An oral SMARCA2 Targeted Glue degrader targets SMARCA4-deficient tumours including non-small cell lung cancer through synthetic lethality, and a pan-TEAD degrader targets Hippo pathway-driven cancers such as mesothelioma and NSCLC; both are preclinical, with data presented at AACR 2026. The company is registered in England and Wales (number 11119959) with its head office at Granta Park, Great Abington, Cambridge.
Notes
top- No financing press release is on the company's current news page (which lists 2026 items only), so funding and investors are empty; the reported 2021 Series B and Merck and Bristol Myers Squibb collaborations were not verified. Founding year not sourced.
Pages like this
not linked directly; found by shared links- CompanyFoghorn Therapeutics
Shares Synthetic lethality approaches, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), Non-small-cell lung cancer.
- CompanyProxygen
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation), Non-small-cell lung cancer.
- CompanyPlexium
Shares Synthetic lethality approaches, PROTACs & molecular glues (targeted protein degradation).
- InstitutionLeicester Cancer Research Centre / University Hospitals of Leicester
Shares Mesothelioma, Non-small-cell lung cancer.
- CompanyPrelude Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), PROTACs & molecular glues (targeted protein degradation).
- PersonKarim Vermaelen
Shares Mesothelioma, Non-small-cell lung cancer.
- PersonStephen B. Baylin
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Non-small-cell lung cancer.
- PersonPierre Fenaux
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.